<DOC>
	<DOCNO>NCT01611155</DOCNO>
	<brief_summary>You ask take part research study go treat oxaliplatin chemotherapy part standard care . Oxaliplatin commonly cause neuropathy ( numbing , tingle and/or pain ) .The purpose study compare effect , good and/or bad , venlafaxine placebo ( inactive agent ) oxaliplatin-induced neuropathy ( numbing , tingle and/or pain )</brief_summary>
	<brief_title>Venlafaxine Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To explore whether venlafaxine prevent ameliorate chronic , cumulative neurotoxicity associate oxaliplatin cancer patient receive oxaliplatin , fluorouracil , leucovorin calcium ( FOLFOX ) . SECONDARY OBJECTIVES : I . To explore whether venlafaxine ameliorate acute neuropathy associate oxaliplatin . TERTIARY OBJECTIVES : I . To explore whether venlafaxine increase cumulative oxaliplatin dos deliver without dose-limiting chronic neurotoxicity . II . To explore whether venlafaxine cause adverse event set . III . To explore whether neuropathy data provide Rydel-Seiffer graduate tune fork consistent patient-reported outcome ( PRO ) measure chemotherapy-induced peripheral neuropathy ( CIPN ) whether tool might cause different result patient receive venlafaxine versus placebo . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive venlafaxine orally ( PO ) twice daily ( BID ) begin day 1 continue completion FOLFOX . ARM II : Patients receive placebo PO BID begin day 1 continue completion FOLFOX . After completion study treatment , patient follow 1 , 3 , 6 , 12 , 18 month .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Scheduled receive FOLFOX chemotherapy individual oxaliplatin dose 85 mg/m^2 per cycle give 2 week cycle ( e.g . modify [ ] FOLFOX6 FOLFOX4 ) Adequate complete blood count ( CBC ) creatinine value ( per attend physician ) obtain = &lt; 28 day prior registration Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 , 1 2 Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Ability complete questionnaire ( ) assistance Life expectancy &gt; = 4 month Strong inhibitor CYP3A4 : &gt; 5fold increase plasma area curve ( AUC ) value 80 % decrease clearance Indinavir ( Crixivan® ) Nelfinavir ( Viracept® ) Atazanavir ( Reyataz® ) Ritonavir ( Norvir® ) Clarithromycin ( Biaxin® , Biaxin XL® ) Itraconazole ( Sporanox® ) Ketoconazole ( Nizoral® ) Nefazodone ( Serzone® ) Saquinavir ( Fortovase® , Invirase® ) Telithromycin ( Ketek® ) Inducers CYP3A4 Efavirenz ( Sustiva® ) Nevirapine ( Viramune® ) Carbamazepine ( Carbatrol® , Epitol® , Equetro™ , Tegretol® , TegretolXR® ) Modafinil ( Provigil® ) Phenobarbital ( Luminal® ) Phenytoin ( Dilantin® , Phenytek® ) Pioglitazone ( Actos® ) Rifabutin ( Mycobutin® ) Rifampin ( Rifadin® ) St. John 's wort Any following : Pregnant woman Nursing woman History allergic reaction , intolerance , venlafaxine Treatment = &lt; 7 day antidepressant , anticonvulsant , monoamine oxidase ( MAO ) inhibitor , neuropathic pain medication agent carbamazepine , phenytoin , valproic acid , gabapentin , lamotrigine , topical lidocaine patch gel , capsaicin cream , amifostine ; addition , may take agent treatment neuropathy , know moderate strong CYP 2D6 ( consist Cinacalcet [ Sensipar™ ] , quinidine , Terbinafine [ Lamisil® , Lamisil AT® ] ) , strong inducer CYP 2D6 terbinafine ( Lamisil® , Lamisil AT® ) , follow drug substantially effect CYP 3A4 Moderate inhibitor CYP3A4 : &gt; 2fold increase plasma AUC value 5080 % decrease clearance Aprepitant ( Emend® ) Erythromycin ( Erythrocin® , E.E.S . ® , EryTab® , Eryc® , EryPed® , PCE® Fluconazole ( Diflucan® ) Grapefruit juice Verapamil ( Calan® , Calan SR® , CoveraHS® , Isoptin SR® , Verelan® , Verelan PM® ) Diltiazem ( Cardizem® , Cardizem CD® , Cardizem LA® , Cardizem SR® , Cartia XT™ , Dilacor XR® , Diltia XT® , Taztia XT™ , Tiazac® ) Other medical condition , opinion treat physician/allied health professional , would make protocol unreasonably hazardous patient Prior neurotoxic chemotherapy Concurrent radiotherapy Current ( within last month ) preexist peripheral neuropathy grade Uncontrolled hypertension ( defined 3 consecutive reading past year 160 systolic , 100 diastolic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>